Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapy of Chronic Lymphocytic Leukemia With Dasatinib
NCT00364286Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2006
- Primary completion
- Nov 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and T-cell prolymphocytic leukemia (T-PLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 3 months. Started Aug 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT00364286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00364286.